Dr. Clay Siegall is the Chief Executive Officer of the Seattle based biotech company Seattle Genetics. The firm focuses on development of specific therapy medicines for ailments whose mortality rate has not changed for decades. Since he founded the company in 1998, Dr. Siegall led the firm to the development of the first FDA approved drug, which later led the firm in securing partnership deals with drug producers such as Genentech, Pfizer, Bayer and others. Through the leadership skills of Dr. Clay Siegall, Seattle Genetics has transformed from a small startup with only a few researchers into a giant firm in the cancer research sector.
During an interview with Inspirery, Dr. Siegall explained that his interest in medicine, technology and how to overcome disease inspired him to venture into business. Initially, Clay was interested in cancer therapy during his college days at the University of Maryland. He believed some cancer treatment therapies like amputation and surgery were brutal and thought of other better and safer ways of doing it. Dr. Siegall generates his income through selling their produced FDA-approved drug, the ADCetris. This drug has been earning good revenues for Seattle Genetics, although they also earn other revenues from strategic partnerships. Dr. Clay Siegall noted that when a drug is approved by FDA, it is an opportunity to get viable market and hence generate lots of money.
Professional Life of Dr. Clay Siegall
Seattle Genetics was co-founded in 1998 by Clay B. Siegall, Ph.D. he also serves as the firm’s CEO, President and chairs the Board. As a trained scientist specializing in cancer therapy, Dr. Clay created his firm on a strong scientific and innovative foundation of extensive research, development of drug and also with a passion of assisting patients.
Under Dr. Siegall’s leadership, Seattle Genetics has emerged as a leader in development of ADCs and also securing FDA approval for ADCETRIS. Through a partnership with Takeda Pharmaceuticals Company, ADCETRIS became an international brand distributed in over 65 countries. The firm also entered into other strategic licenses with companies like AbbVie, Pfizer, GlaxoSmithKline and Genentech which have earned revenues worth $350 million to date.